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Abstract
The cyclic nature of the capillary bed in the corpus luteum offers a unique experimental model to
examine the life cycle of endothelial cells, involving discrete physiologically regulated steps of
angiogenesis, blood vessel maturation and blood vessel regression. The granulosa cells and theca
cells of the developing antral follicle and the steroidogenic cells of the corpus luteum produce and
respond to angiogenic factors and vasoactive peptides. Following ovulation the neovascularization
during the early stages of corpus luteum development has been compared to the rapid angiogenesis
observed during tumor formation. On the other end of the spectrum, the microvascular
endothelial cells are the first cells to undergo apoptosis at the onset of corpus luteum regression.
Important insights on the morphology and function of luteal endothelial cells have been gained from
a combination of in vitro and in vivo studies on endothelial cells. Endothelial cells communicate with
cells comprising the functional unit of the corpus luteum, i.e., other vascular cells, steroidogenic
cells, and immune cells. This review is designed to provide an overview of the types of endothelial
cells present in the corpus luteum and their involvement in corpus luteum development and
regression. Available evidence indicates that microvascular endothelial cells of the corpus luteum
are not alike, and may differ during the process of angiogenesis and angioregression. The
contributions of vasoactive peptides generated by the luteal endothelin-1 and the renin-angiotensin
systems are discussed in context with the function of endothelial cells during corpus luteum
formation and regression. The ability of two cytokines, tumor necrosis factor alpha and interferon
gamma, are evaluated as paracrine mediators of endothelial cell function during angioregression.
Finally, chemokines are discussed as a vital endothelial cell secretory products that contribute to
the recruitment of eosinophils and macrophages. The review highlights areas for future
investigation of ovarian microvascular endothelial cells. The potential clinical applications of
research directed on corpus luteum endothelial cells are intriguing considering reproductive
processes in which vascular dysfunctions may play a role such as ovarian failure, polycystic ovary
syndrome (PCOS), and ovarian hyperstimulation syndrome (OHSS).
Background
The vascular endothelium of the mature ovarian follicle
maintains the capacity for rapid growth in response to
angiogenic signals elaborated during the periovulatory
process. New blood vessel growth is essential for the for-
mation and function of the corpus luteum. Analogous to
Published: 10 November 2003
Reproductive Biology and Endocrinology 2003, 1:89
Received: 18 July 2003
Accepted: 10 November 2003
This article is available from: http://www.rbej.com/content/1/1/89
© 2003 Davis et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
Page 2 of 15
(page number not for citation purposes)
events occurring in the corpus luteum, the vascular
endothelium of other tissues responds to extracellular sig-
nals during the physiologic processes of embryonic devel-
opment and wound healing, and in the pathologic
process of tumor angiogenesis. Although the corpus
luteum is a transient tissue, it is one of the most highly
vascularized tissues in the body [1] with endothelial cells
representing greater than fifty percent of the total cells
[2,3]. Endothelial cell proliferation and vascular changes
have been examined throughout the luteal phase in rat
[4,5], rabbit [6], pig [7], sheep [8,9], cow [10-13], horse
[14], marmoset [15], macaque [16], and human [17] cor-
pora lutea. The vascular elements in these studies were
determined using markers of endothelial cells (von Wille-
brand factor VIII related antigen, FVIIIr antigen; angi-
otensin-converting enzyme, ACE; lectin binding, e.g.,
Griffonia Simplicifolia agglutinin and Ulex Europaeus
agglutinin; and platelet/endothelial cell adhesion mole-
cule-1, PECAM-1). Evidence of proliferating endothelial
cells was determined by the presence of Ki-67 antigen-
positive cells, bromodeoxyuridine-positive cells, or [3H]
thymidine-positive cells. Collectively, these studies dem-
onstrate that the rate of endothelial cell proliferation is
highest during corpus luteum formation, then decreases
and remains low during the mid-luteal phase and struc-
tural regression of the corpus luteum. The establishment
of an extensive vascular network is an essential compo-
nent of corpus luteum development, since the inhibition
of angiogenesis during corpus luteum formation is associ-
ated with inadequate corpus luteum function [3,12,18-
21].
The regulation of endothelial cell proliferation in the cor-
pus luteum of pregnancy is less clear. Treatment with
human chorionic gonadotropin (hCG) to simulate early
pregnancy resulted in elevated progesterone secretion and
sustained luteal weight but was not associated with an
increase or maintenance of endothelial cell proliferation
in monkeys or humans [16,17]. However, more recent
morphometric evidence [22] suggests that hCG rescue of
the human corpus luteum is associated with a second
wave of angiogenesis and vascular stabilization.
The onset of the structural regression of the corpus luteum
involves alterations in the vascular elements of the corpus
luteum [12,23-28]. The endothelial cells lose tight junc-
tions and the permeability barrier of the vascular wall is
disrupted. As a result, capillary endothelial cells detach
from the basement membrane and occlude small blood
vessels. Capillaries disappear, whereas arterioles with a
thickened wall appear, apparently as a result of increased
numbers of smooth muscle cells [14,15,29]. It has been
suggested that the arteriole thickening during corpus
luteum regression represents a degenerative event [30].
The observed alterations in endothelial cell degeneration
clearly demonstrate vascular changes concurrent with a
reduction in the functional status of the corpus luteum.
Given the pivotal role that endothelial cells play in corpus
luteum formation, maintenance and regression it is criti-
cal to understand the nature of the microvascular
endothelial cells at various stages during the life span of
the corpus luteum. The goal of this review is to summarize
what is known about the morphological and functional
characteristics of the microvascular endothelial cells of the
corpus luteum. This review also summarizes evidence for
the regulation of luteal endothelial cells by vasoactive
peptides (angiotensin II and endothelin-1) and cytokines
(tumor necrosis factor alpha and interferon gamma) dur-
ing angiogenesis and/or angioregression. The review also
discusses chemokines as endothelial cell secretory prod-
ucts that contribute to the recruitment of eosinophils and
macrophages. A greater understanding of the specific
endothelial cell types involved in the angiogenic response
during corpus luteum formation and the vascular regres-
sion during structural regression will enable a greater
appreciation for the endocrine, paracrine, and autocrine
factors; intercellular cross-talk; and specific signaling
mechanisms that control corpus luteum function.
Endothelial cells of the corpus luteum
Morphological characteristics
Over the past twenty years microvascular endothelial cells
have been isolated from the corpora lutea of different spe-
cies: the rabbit [31], pig [32], sheep [33], cow [34-38],
rhesus monkey [39], and human [40]. These studies have
provided important clues about the presence and role of
specific endothelial cells types found in the corpus luteum
despite species differences and various methods for
endothelial cell isolation and culture. The ability to suc-
cessfully freeze and recover endothelial cells from frozen
stocks has allowed the opportunity to further explore
endothelial cell function in vitro. Together these studies
provide evidence for in vitro regulation of the prolifera-
tion, function and demise of luteal endothelial cells.
Although all endothelial cells have some common func-
tional and/or morphological characteristics; the endothe-
lial cells of large and small blood vessels from either the
same or different organs vary in morphology, surface mol-
ecule expression, and function. A substantial amount of
information has been accumulated on endothelial cells
from the bovine corpus luteum [34-38]. Five distinct sub-
types of bovine microvascular endothelial cells have been
characterized by different morphology, surface molecule
expression and function [34,41-47]. Each cell type exhib-
ited contact-inhibited growth and maintained unique
morphological characteristics in long-term culture. Figure
1 shows representative phase-contrast photomicrographs
and growth curves for each of the five cell types.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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The five different endothelial cell types derived from bovine corpus luteum are shown by phase contrast microscopy as  described by Spanel-Borowski and van der Bosch [41] and Fenyves et al Figure 1
The five different endothelial cell types derived from bovine corpus luteum are shown by phase contrast microscopy as 
described by Spanel-Borowski and van der Bosch [41] and Fenyves et al., [44]. Panels a–f: In cytokeratin-positive cell types 1 
and 2, the cobble-stone like pattern is distinct (panels a and b); in cytokeratin-negative cells, the monlayer consists of spindle-
like cells with prominent "vacuoles" in cell type 3 (panel c); the monlayer of polygonal opaque cells appear in cell type 4 (panel 
d). Type 5 cells are judged as granulosa-like cells (panel e). The five cell types differ in growth rate (panel f).
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Monolayers of type 1 and 2 cells appear as polygonal epi-
thelioid cells with a prominent cobblestone pattern. Cells
of type 3 form a polymorphic monolayer with spindle-
shaped cells with and without intracytoplasmic vacuoles.
Cells of type 4 form a monolayer of round cells with an
opaque appearance, while type 5 cells form a monolayer
of polygonal cells with a flat phase-dense appearance.
With the notable exception of type 5 cells, the cells of
types 1–4 form tubules. Immunocytochemical staining
revealed that each of the five types of endothelial cells
expresses FVIIIr antigen. The FVIIIr antigen staining varies
among the cell types; type 1 cells exhibit a diffuse perinu-
clear pattern and type 3 cells exhibit a distinctive granular
pattern (Figures 2a and 2b). All types of endothelial cells
express ACE, and they internalize acetylated low-density
lipoprotein (Ac-LDL).
Each endothelial cell type displays a unique pattern of
microtubules; actin and vimentin filaments; and fibronec-
tin matrix [45-49]. Figures 2c and 2d demonstrate the dis-
tinctive actin filament arrangement in type 1 and type 3
endothelial cells. The type 1 cells express E-cadherin as a
molecule of adhesion plaques, while only the type 5 cells
display N-cadherin molecules. Furthermore, the expres-
sion of neuronal cell adhesion molecule (NCAM-140) is
found in cell types 1, 2 and 5, but not types 3 and 4 [48].
The immunoreactivity of NCAM-140 in cell type 1 is local-
ized to the perinuclear region, whereas, in types 2 and 5 it
is predominately localized at the lateral surface outlining
the contact zones between adjacent cells. It seems likely
that NCAM-140 may play a role in maintaining the exten-
sive contact observed between microvascular endothelial
cells and steroidogenic cells of the corpus luteum.
Distinctive morphological features of type 1 and type 3 endothelial cells Figure 2
Distinctive morphological features of type 1 and type 3 endothelial cells. Panels a and b: Staining for von Willebrand factor VIII 
related antigen (FVIIIr antigen) shows a diffuse perinuclear pattern in type 1 cells (panel a) and a distinctive granular appearance 
in type 3 cells (panel b). Panels c-d: Immunofluorescence for actin filaments using phalloidin-FITC. The cytokeratin-positive 
(CK-positive) type 1 cells demonstrate a peripheral band of microfilaments (panel c); the cytokeratin-negative (CK-negative) 
cells of type 3 show a starburst-like pattern (panel d) [44].
b a F VIII r antigen, type 1 cells F VIII r antigen, type 3 cells
phalloidin-FITC, type 1 cells phalloidin-FITC, type 3 cells d cReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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Of the original classifications of bovine microvascular
endothelial cells, the type 5 endothelial cells are now
thought to represent immature granulosa cells [50]. The
type 5 cells and granulosa cells have similar morphologi-
cal features in vitro, and the type 5 endothelial cells have
characteristics different from other endothelial cell types.
Type 5 cells exhibit weak staining for FVIIIr antigen and
ACE [45], and display overlapping cell borders as deter-
mined by electron microscopy [49], and N-cadherin
expression [45] that are not present in the contact-inhib-
ited microvascular endothelial cells. When compared
simultaneously, type 5 cells display features similar to
bovine granulosa cells isolated from small antral follicles
[50], i.e., the endothelial cells have morphological charac-
teristics of granulosa cells, produce small quantities of
progesterone and are unresponsive to treatment with
luteinizing hormone (LH). Spanel-Borowski et al. [50]
suggested that these cells may represent stem cells for the
renewal of luteal cells. More recently, Antczak and Van
Blerkom [51] proposed that subpopulations of human
and murine ovarian granulosa cells behave as specialized
endothelial-like cells. They demonstrated that granulosa
cells possess many markers used for the identification of
endothelial cells. Furthermore, some subpopulations of
granulosa cells engage in tubule-forming activity and pro-
duce a range of molecules in response to hypoxia [52].
The overlapping phenotypes presented in these studies
using mouse, bovine and human ovarian cells suggest that
under the appropriate conditions granulosa cells may per-
form functions normally ascribed to endothelial cells and
vice versa. Studies are needed to determine whether a
common stem cell present in the ovary contributes to the
development of follicles and vascular cells.
Microvascular endothelial cells of the bovine corpus
luteum have been also classified by the presence or
absence of cytokeratin 8, 9, and 18 filaments [34,41-49].
Type 1 and 2 endothelial cells contain these cytokeratins
and, in vitro, they display characteristics similar to cytoker-
atin-positive endothelial cells from the aorta [53]. Based
on their limited appearance in the corpus luteum, the
cytokeratin-positive endothelial cells have been classified
as a rare luteal microvascular endothelial cell type. While
both cytokeratin-positive and negative endothelial cells
share characteristics typical of other endothelial cells (typ-
ical lectin binding patterns [46], positive for FVIIIr and
internalization of Ac-LDL [54]), the cytokeratin-negative
cells exhibit five-fold greater FVIIIr antigen binding and
ten-fold greater Ac-LDL uptake [54] than the cytokeratin-
positive cells. The cytokeratin-negative cells also have a
greater proliferation rate than do the cytokeratin-positive
cells [44]. The cytokeratin-positive cells produce tubules
with helically arranged cells originating from a trunk-like
structure in vitro [Figure 3a], whereas the cytokeratin-neg-
ative cells spontaneously form tubules that develop into a
prominent tubule network as shown in Figures 3b and
3c[41,45].
Of the various types of endothelial cells, the cytokeratin-
positive cells are predominantly found in the early stages
of bovine corpus luteum development, and to a much
lesser extent in functional and regressing corpora lutea of
the estrous cycle, and almost never in the corpus luteum
of pregnancy [49]. The cytokeratin-positive endothelial
cells are observed in the corpus luteum at the onset of ang-
iogenesis and are often located at the branching point, or
tips of sprouting capillaries. The expression of specific
keratins may provide some advantage, since epithelial
cells expressing keratins 8 and 18, are less susceptible to
cytokine-mediated apoptosis [55]. The endothelial cell
types also differ in their expression of adhesion molecules
[54], recruitment of leukocytes [56], and ability to form
intercellular junctions [57]. These in vitro and  in vivo
results, together with the selective presence of cytokeratin-
positive cells in early corpus luteum development, pro-
vide evidence that cytokeratin-positive microvascular
endothelial cells are morphologically and functionally
different from the common cytokeratin-negative endothe-
lial cell in the corpus luteum. Both cytokeratin-positive
and -negative cell types are likely to be involved in blood
vessel formation, maintenance and regression; yet exert-
ing their influence in these events differently.
In the corpus luteum, microvascular endothelial cells are
likely to mediate the cyclic accumulation of specific sub-
sets of leukocytes [58-61] by the expression of cell adhe-
sion factors [54-57] and secretion of chemokines [60-64].
Adhesion molecules expressed on endothelial cells are
involved in cell migration, maintaining intercellular con-
tacts and anchoring cells to the extracellular matrix. Rest-
ing cytokeratin-positive endothelial cells contain the cell
adhesion factors CD-29, CD-31 (PECAM-1), CD-49A and
CD-49E (integrin α5), but the level of expression is signif-
icantly lower than in cytokeratin-negative endothelial
cells [54]. In contrast to the cytokeratin-negative cells, the
cytokeratin-positive cells fail to express CD-49B (integrin
α2), or MHC Class II [54]. Each of the endothelial cell
types differs in their basal and interleukin-1 stimulated
adhesion of granulocytes [56]. These results suggest that
different types of endothelial cells have unique extracellu-
lar matrix-endothelial cell interactions and are differen-
tially involved in the selective attachment and migration
of leukocytes into the corpus luteum.
Differences in morphology, cell growth patterns, and lec-
tin binding parameters have also been reported for micro-
vascular endothelial cells isolated from corpora lutea of
pregnant (second trimester) and non-pregnant (mid
luteal phase) cows. Plendl et al. [36] used a flow cytometry
approach to isolate endothelial cells from these physio-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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Endothelial cells of the bovine corpus luteum form tubule-like structures in vitro as demonstrated by scanning electron micros- copy [41,42] Figure 3
Endothelial cells of the bovine corpus luteum form tubule-like structures in vitro as demonstrated by scanning electron micros-
copy [41,42]. Panel a: In cytokeratin-positive, type 1 cell cultures, the tubule-like structures derive from a junction point and 
develop distinct borders. A longitudinal cut through a cytokeratin-positive tubule reveals the "inside out" model, i.e. a core of 
extracellular matrix. Panel b: In cytokeratin-negative, type 3 cells the tubule-like structures depict a reticular network without 
distincl cell borders. True tubules are formed as verified by the presence of an extracellular matrix core. Panel c: Cytokeratin-
negative, type 4 cell cultures form a reticular arrangement of pseudo-tubules lacking the three-dimensional structure of true 
tubules (panel c).
CK-positive, type 1  cells
CK-negative, type 3  cells
CK-negative cells, type 4
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c
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logic distinct luteal tissues. Bovine corpora lutea from
pregnant and non-pregnant animals each produced two
populations of endothelial cells that were characterized as
either having a cobblestone growth pattern or an arcuate
growth pattern. Cultures of endothelial cells of the corpus
luteum of pregnancy exhibited spontaneous angiogenic
activities including cell migration and formation of ring-
like structures. These intriguing observations lead Plendl
et al. [36] to speculate that the endothelial cells isolated
during pregnancy produce specific angiogenic factors not
present or present in limited quantities in endothelial
cells isolated from the corpus luteum of the estrous cycle.
Heterogeneity between luteal endothelial cells of preg-
nant and non-pregnant animals was also observed in lec-
tin binding studies which revealed that specific
endothelial cell surface carbohydrates were correlated to
the status of pregnancy [36].
Angiogenic factors and receptors
The maturation of preovulatory follicles as a prelude to
ovulation and corpus luteum formation requires the
development of a microvasculature sufficient for the
delivery of adequate levels of hormones and lipoprotein-
bound cholesterol. It has been appreciated that the granu-
losa cells and theca cells of the developing follicle produce
angiogenic activities [65,66]. Following ovulation, the
burst in blood vessel growth during the onset of corpus
luteum development has been compared to the rapid ang-
iogenesis observed during tumor formation. The ang-
iogenic activities produced by granulosa, theca and
steroidogenic luteal cells have been ascribed to basic
fibroblastic growth factor (bFGF) and to vascular
endothelial cell growth factor (VEGF). Conversely, micro-
vascular endothelial cells also produce these growth fac-
tors and thus support their own mitosis as well as that of
granulosa cells [67]. VEGF and probably bFGF serve as
angiogenic factors as well as survival factors for microvas-
cular endothelial cells [3,68].
It is well established that the development of a vascular
bed comprises a coordinated collaboration between VEGF
and its receptors, fms-like tyrosine kinase-1 receptor (Flt-
1) and Flk-1 (fms-like kinase insert domain-containing
receptor, a.k.a. KDR). As discussed in recent reviews
[12,18-20], each of these components is present in the
corpus luteum of rodents, farm animals and primates.
Available evidence indicates that both mRNA and protein
for VEGF and its receptors are highly expressed in the
newly formed corpus luteum, maintained, albeit at lower
levels, in the mid-luteal phase, and then decreased dra-
matically during corpus luteum regression. Based on in
situ  hybridization and immunohistochemistry studies
VEGF is present mainly in steroidogenic luteal cells, while
Flt-1 and Flk-1 appear to be present in both steroidogenic
cells and endothelial cells in human corpora lutea [69-
71], but only in the endothelial cells of bovine corpora
lutea [68-72]. A recent report by Tscheudschilsuren et al.
[73] on the expression of angiogenic factors and their
receptors in cytokeratin-positive and -negative microvas-
cular endothelial cells from the bovine corpus luteum
shows that both types of microvascular endothelial cells
produce VEGF mRNA. Thus, based on reverse tran-
scriptase-polymerase chain reaction (RT-PCR) and immu-
nohistochemical analysis, follicular granulosa and theca
cells as well as steroidogenic luteal cells are not the sole
source of VEGF in the bovine ovary. Both endothelial cell
types also possess mRNA for the Flt-1 receptor. Further
analysis revealed that cytokeratin-negative, but not cytok-
eratin-positive cells, contain Flk-1 mRNA. Based on RT-
PCR analysis cytokeratin-negative cells possess Flk-1
mRNA levels 100 times greater than that of Flt-1 [73].
Additional angiogenic factors, such as the angiopoietins
are also implicated in the regulation vascular develop-
ment and regression [74]. Angiopoietin-1 and angiopoie-
tin-2 are ligands for the Tie-2 receptor (tyrosine kinase
with immunoglobulin and epidermal growth factor
homology domains). Angiopoietin-1 stimulates sprout-
ing and maturation of blood vessels in vitro, whereas angi-
opoietin-2 inhibits this effect by acting as a competitive
inhibitor by binding to the Tie-2 receptor without activat-
ing intracellular signaling pathways. In the bovine corpus
luteum, similar levels of angiopoietin-1 and angiopoietin-
2 mRNA are present in developing and fully functional
corpora lutea of the estrous cycle [68]. However, the angi-
opoietin-2 to angiopoietin-1 ratio shifts markedly during
blood vessel regression. It has been suggested that eleva-
tion of angiopoietin-2 results in regression of the corpus
luteum [68,75]. Neither cytokeratin-positive or -negative
endothelial cell types contain angiopoietin-1 mRNA,
whereas only cytokeratin-negative endothelial cells con-
tain mRNA for angiopoietin-2 [73]. These results further
underscore the differences in these cell types. Also of inter-
est in these studies are the observations that hypoxia,
which may play a role in the initial process of luteal vas-
cularization [76] had no effect on the levels of mRNA for
hypoxia-induced transcription factors, HIF-1α and HIF-1β
[73]. Hypoxia did not alter the levels of VEGF, Flk-1 or Tie-
2 mRNA in cytokeratin-positive or negative endothelial
cells. However, hypoxia did elevate Flt-1 and angiopoie-
tin-2 mRNA levels in cytokeratin-negative cells. At
present, it is unclear whether the mRNA for angiogenic
factors and their receptors are efficiently translated into
protein and have functional significance in the intact cor-
pus luteum. If so, this would indicate that luteal endothe-
lial cells are not only responsive to, but also actively
contribute angiogenic signals in support of the angiogenic
factors produced by the steroidogenic cells.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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As a sign of in vitro angiogenesis, tubules form in four to
six week-old confluent cultures of bovine endothelial cell
types 1–4 [44]. The tubules represent a true three-dimen-
sional "inside out" model with the apical cell side towards
the culture medium and the basal side towards a core of
extracellular matrix. Tubules formed by cytokeratin-posi-
tive endothelial cells have a braided-like aspect in the
scanning electron microscope because of distinct cell
boarders arranged helically around the tube axis [Figure
3a]. Since small arterioles of the human ureter show a
similar endothelial cell helix in microvessel corrosion
casts [77], the cytokeratin-positive tubules may represent
arteriole-like tubules. Tubules of cytokeratin-negative type
3 endothelial cells have a smooth surface texture and are
anchored to the monolayer by extremely long cell proc-
esses [Figure 3b]. Cytokeratin-negative type 4 cells form
pseudotubules having a two-dimensional reticular
appearance (Figure 3c) [41]. The differences in tubule for-
mation further underscore the different endothelial cell
types and point to possible differences in the origin of the
microvascular bed and the involvement of different ang-
iogenic factors (or the lack thereof) in tubule formation.
The signaling pathways that regulate angiogenesis of the
corpus luteum are poorly understood. The receptors for
angiogenic factors are analogous to other growth factor
receptor tyrosine kinases. Studies employing endothelial
cells from other tissues suggest that the phosphatidyli-
nositol 3-kinase/Akt-signaling pathway is a key regulator
of the angiogenic phenotype and survival of endothelial
cells [reviewed in [78]]. More recently, glycogen synthase
kinase-3β (GSK-3β) has been suggested to be an essential
signaling mediator for controlling endothelial survival
and migration in vitro and angiogenesis in vivo [79]. In
these studies, GSK-3β was characterized as being under
the control of Akt and mitogen-activated protein kinase
signaling pathways. Thus, GSK-3β may serve as a point of
conversion for multiple signaling pathways that coordi-
nate endothelial responses to different angiogenic inputs.
It will be important to discover the signaling pathways
necessary to promote the rapid vascularization of the cor-
pus luteum and the signaling pathways required for main-
taining this elaborate vascular network.
Regulation by vasoactive peptides
Renin-Angiotensin System
Components of the renin-angiotensin system have been
identified in the ovaries of a number of species [80]. A role
for angiotensin II has been proposed in growth and atresia
of follicles, oocyte maturation, ovulation, corpus luteum
formation, steroidogenesis, and corpus luteum regression.
Angiotensin I is produced from the precursor angi-
otensinogen by the enzymatic activity of renin, which is
located in granulosa, theca and luteal cells [80,81]. Micro-
vascular endothelial cells characteristically possess the
angiotensin-converting enzyme (ACE) and are capable of
converting angiotensin I into angiotensin II. In the bovine
corpus luteum, tissue levels of angiotensin II remain con-
stant throughout the estrous cycle, although levels of angi-
otensin II are higher in the ovarian vein than the jugular
vein [82,83]. Early studies using pharmacologic
approaches indicate that receptors for angiotensin II are
present on steroidogenic cells; however, the presence of
either angiotensin II type 1 (AT1R) or type 2 (AT2R)
receptors varies among species [80]. Recent studies using
a semi-quantitative RT-PCR approach indicate that bovine
luteal cells and microvascular endothelial cells possess
both AT1R and AT2R [81,82]. AT1R expression did not
change over the bovine estrous cycle, while AT2R expres-
sion was lowest during the mid luteal phase and highest
during the late luteal phase.
Angiogenesis
Available evidence suggests that angiotensin II may play a
role in early corpus luteum development. Angiotensin II
has been shown to stimulate the mRNA levels for bFGF in
bovine luteal cells [84] and increase the proliferation of
bovine aortic endothelial cells [85]. Furthermore, estra-
diol in combination with either VEGF or bFGF increases
the production of angiotensin II in cytokeratin-negative
type 3 bovine luteal endothelial cells [81]. In bovine cor-
pora lutea collected during the early luteal stage (days 1–
4), infusion of VEGF or bFGF using an in vitro microdial-
ysis system stimulated the secretion of angiotensin II, pro-
gesterone and prostaglandin F2α [86]. Angiotensin II
administration using either in vitro [86] or in vivo [83]
microdialysis systems stimulated progesterone secretion
from early luteal phase corpora lutea. Although a direct
cause and effect relationship remains to be established, it
appears that the renin-angiotensin system is active during
the early luteal phase and endothelial cells are involved.
Angioregression
In contrast to a supportive role in early corpus luteum
development, angiotensin II may facilitate functional and
structural regression of the corpus luteum. During the mid
luteal phase treatment with prostaglandin F2α in vivo had
no effect on levels of mRNA for either AT1R or AT2R (87).
It did, however, enhance luteal ACE mRNA levels,
increase levels of immunoreactive angiotensin II in
endothelial cells and large luteal cells, and increase the
secretion of angiotensin II [87]. In contrast, prostaglandin
F2α had no direct effect on angiotensin II production in
isolated microvascular endothelial cells in vitro [82].
Angiotensin II inhibits LH-stimulated progesterone secre-
tion from primary cultures of bovine corpora lutea cells
[84] and from mid luteal phase bovine corpora lutea in an
in vitro microdialysis system [87,88]. Furthermore, angi-
otensin II, together with prostaglandin F2α, has a markedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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suppressive effect on progesterone secretion in vivo and
hastens luteal regression [89]. Although a direct cytotoxic
effect of angiotensin II on the luteal endothelial or ster-
oidogenic cells has not been reported, in other tissues
angiotensin II has been shown to directly induce apopto-
sis of microvascular endothelial cells and parenchymal
cells [reviewed in Filippatos et al., [90]]. A complex inter-
action is emerging among various principles that regulate
angiotensin II secretion and its action in the corpus
luteum. The contribution of vascular endothelial cells
cannot be understated in this context. Experiments
designed to determine the actions of angiotensin II on
endothelial cells are clearly required for a deeper under-
standing of the events leading to angioregression.
Endothelin-1
Endothelin-1 is a potent vasoconstrictor and mitogen for
endothelial cells, vascular smooth-muscle cells and vari-
ous tumor cells [91]. Endothelin-1 expression correlates
with the vascularization of tumors [92] and the malig-
nancy in ovarian cancer [93]. Endothelin-1 also acts as a
cell survival factor for rat fibroblasts, vascular smooth
muscle cells, and endothelial cells [90]. The endothelins
exert their physiological effects via two receptors,
endothelin type A (ETA) and type B (ETB) receptors. The
ET receptors are G-protein-coupled transmembrane recep-
tors found in both vascular and nonvascular tissues.
Endothelin-1 suppresses or induces apoptosis depending
on cell type and cell-specific expression of ETA and ETB
receptor subtypes [90]. The anti-apoptotic effects of the
ETA receptor are presumptively mediated through activa-
tion of the mitogen-activated protein kinase signaling sys-
tem. In contrast, endothelin-1 may promote apoptosis by
acting through ETB receptors [90]. Despite the close rela-
tionship between endothelin-1 and vascular function, lit-
tle is understood about the role of endothelin-1 in the
regulation of blood vessel formation and maintenance in
the corpus luteum.
Angiogenesis
The corpus luteum has a complete endothelin system that
is influenced by endocrine and paracrine factors.
Endothelin-1 (ET-1) is synthesized by proteolytic cleavage
of a large precursor molecule, prepro endothelin-1, which
is facilitated by a metalloproteinase, endothelin convert-
ing enzyme (ECE). In the bovine corpus luteum, prepro
endothelin-1 mRNA appears to be expressed only in
endothelial cells whereas, both the steroidogenic cells and
luteal endothelial cells express ECE [87,94-96]. Thus, the
steroidogenic cells and endothelial cells may differentially
cooperate in the biosynthesis of mature endothelin-1. The
ECE is expressed in the corpus luteum throughout the
normal estrous or menstrual cycle [94-96]. However, ECE
mRNA and protein levels peak at mid luteal phase and are
reduced during corpus luteum regression suggesting that
endothelin-1 plays a role in corpus luteum development.
A recent report [94] describes two ECE isoforms, ECE-1a
and ECE-1b, in steroidogenic cells and cytokeratin-nega-
tive endothelial cells of the bovine corpus luteum. Based
on their cellular localization, the isoforms are capable of
cleaving the intra- or extra-cellular endothelin-1 precursor
molecule, respectively. Endothelial cells posses mRNA for
both ECE-1 isoforms, whereas the steroidogenic cells pos-
ses only mRNA for the extracellular ECE-1b isoform.
Treatment with LH and endothelin-1 for 24 hours down
regulated ECE-1b mRNA levels, providing a preliminary
indication that hormonal and feedback regulatory mech-
anisms may control the level of ECE-1 activity and ulti-
mately endothelin-1 levels in the corpus luteum [94].
Other evidence suggests that in cultures of luteinized
bovine and human granulosa cells treatment for periods
of 4–5 days with either insulin-like growth factor-I (IGF-I)
[94] or hCG [97] up regulates ECE levels. Thus, a complex
pattern of ECE regulation may occur depending on the
specific stage of follicle or corpus luteum development. In
other systems endothelin-1 has been shown to stimulate
endothelial cell growth through stimulation of VEGF pro-
duction, and VEGF has been shown to stimulate endothe-
lin-1 secretion [91]. Since VEGF and endothelin-1 protein
are expressed in the newly ruptured follicle [68,94], it
seems possible that endothelin-1 potentiates VEGF medi-
ated angiogenesis in the developing corpus luteum.
Angioregression
Endothelin-1 has been implicated as a mediator of func-
tional corpus luteum regression (reduced steroid synthe-
sis, yet intact structure) in rat [98], ovine [99], bovine,
[100] and human [101] luteal tissues. Although treatment
with endothelin-1 has no effect on angiotensin II,
oxytocin, progesterone or prostaglandin F2α secretion
during the early luteal phase [83,86], endothelin-1
appears to play an essential role during prostaglandin
F2α-induced regression of corpora lutea during the mid
luteal phase. Following the administration of a sub-luteo-
lytic dose of a prostaglandin F2α analogue during the mid
luteal phase in cows, an intraluteal injection of endothe-
lin-1 results in a rapid decrease in plasma progesterone
[99]. Furthermore, intraluteal injection of an endothelin-
1 receptor antagonist before administration of a luteolytic
dose of prostaglandin F2α reduces the response to pros-
taglandin F2α [102].
Receptors for endothelin-1 have been documented in cor-
pora lutea of many species [87,94,97,103,104]. The ETA
and ETB  receptors are present in the bovine ovary
throughout the estrous cycle and pregnancy, but levels of
ETB are elevated around the time of spontaneous corpus
luteum regression [87,96]. Although it is clear that the
steroidogenic cells and endothelial cells of the corpus
luteum have receptors for and respond to endothelin-1,Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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detailed studies on the specific receptors present in
endothelial cells are sparse. In autoradiographic studies of
the human ovary [104], ETA and ETB were localized to the
blood vessels, with ETB  predominantly localized to
endothelial cells and ETA localized to the smooth muscle
of the vascular wall. In situ hybridization studies [103] of
monkey and human ovaries revealed that ETA receptor
mRNA was predominantly located in smooth muscle cells
of blood vessels adjacent to follicles and corpora lutea.
The ETB receptor mRNA was localized to the endothelial
cells lining the blood vessels of corpora lutea. As deter-
mined by RT-PCR analysis of purified populations of
bovine corpora lutea cells, cytokeratin-negative endothe-
lial cells contain levels of ETA mRNA greater than those
found in either the large or small luteal cells [105]. Much
work is required to clarify the cellular distribution of
endothelin receptors among species and luteal cell types.
Endothelin-1 (ET-1) peptide and ETB mRNA levels are ele-
vated during spontaneous corpus luteum regression [96].
Furthermore, administration of prostaglandin F2α at mid-
cycle elevates mRNA levels for ECE, endothelin-1, ETA and
ETB, as well as increasing endothelin-1 peptide expression
in the bovine corpus luteum [87,94-96,98,99]. As deter-
mined by immunocytochemistry the increases in
endothelin-1 occur in the large luteal cells and the
endothelial cells [87]. These results suggest a functional
role for endothelin-1 in the blood vessel changes observed
in regressing corpus luteum. Perhaps endothelin-1 serves
to coordinate the regression of capillaries, and the degen-
erative process in arterioles (arteriolarization) observed in
the regressing corpus luteum [30]. This idea would be
consistent with the observed increases in the proliferation
of vascular smooth muscle cells and possibly pericytes
during corpus luteum regression [14,15,29]. Currently,
there is no evidence that endothelin-1 plays a role in the
structural regression of the corpus luteum by directly
affecting the viability of steroidogenic or endothelial cells,
such as assumed for the renin-angiotensin system [90].
Studies to examine the actions of endothelin-1 in combi-
nation with other vasoactive peptides and cytokines may
be required to reveal cytotoxic effects of endothelin-1.
Regulation by Cytokines
Role of Tumor Necrosis Factor Alpha (TNFα) in 
Angioregression
The cytokine TNFα exerts many actions on the corpus
luteum [61,106,107]. Although it is generally assumed
that immune cells contribute to intraovarian TNFα,
endothelial cells and macrophages of the porcine corpora
lutea secrete TNFα [108]. The steroidogenic cells and
endothelial cells of the corpus luteum possess receptors
for TNFα (TNFR) [109-111]. Levels of TNFR1 mRNA were
elevated in physiologic or prostaglandin F2α-induced
regression of the corpus luteum [111]. Microvascular
cytokeratin-negative endothelial cells isolated from the
bovine corpus luteum possess TNFR1. Furthermore, TNFα
receptors are functionally coupled in microvascular
endothelial cells to an increase in the production of both
endothelin-1 and prostaglandin E2 [110]. As stated in the
previous section, endothelin-1 has the ability to reduce
progesterone secretion from the mid cycle bovine corpus
luteum in vitro and in vivo. It seems likely, therefore, that
TNFα-induced endothelin-1 secretion from endothelial
cells may act in a paracrine manner to influence the ster-
oidogenic capacity of luteal cells.
Two recent reports employing primary cultures of bovine
luteal endothelial cells demonstrate that TNFα is cytotoxic
for endothelial cells derived from the corpus luteum
[38,111]. Apoptosis of luteal endothelial cells in response
to TNFα was associated with both morphological and bio-
chemical features of apoptosis, including shrunken
nuclei, DNA fragmentation, and caspase-3 activation. In
contrast, neither Fas ligand nor prostaglandin F2α altered
the viability of these cells [38]. TNFα-induced cell death
was associated with a rapid activation of members of the
mitogen-activated protein kinase family (ERK, p38 and
JNK), as well as, the activation of sphingomyelinase with
a resultant accumulation of the second messenger cera-
mide [38]. Treatment with ceramide elevated the activity
of JNK and induced apoptosis in endothelial cells. Of con-
siderable interest were observations that pretreatment of
endothelial cells with glutathione, an intracellular reduc-
ing agent and known inhibitor of reactive oxygen species,
significantly attenuated TNFα-induced apoptosis [38].
These data suggest that TNFα or a member of this cytokine
superfamily, may mediate the actions of prostaglandin
F2α on regression of the microvascular capillary beds dur-
ing structural regression of the corpus luteum in vivo.
Role of Interferon gamma (IFNγ) in Angioregression
The cytokine IFNγ exerts anti-proliferative effects on a
number of primary cells and cell lines. This cytokine
prominently figures in the regulation of corpus luteum
function [61,106,107] and has a variety of effects on
bovine luteal endothelial cells types 1–5. Under confluent
monolayer culture conditions, treatment with IFNγ for
three days resulted in a flattening and enlargement of cell
types 1–4, with less evident changes in the morphology in
cell type 5 [44,45]. In cytokeratin-negative cells of type 3,
large intracytoplasmic vacuoles were present following
treatment with IFNγ. These morphological changes were
considered to be signs of senescence. Treatment with IFNγ
also caused dramatic alterations in the actin cytoskeleton
of endothelial cells types 1, 3, 4 and 5 [45] and generally
reduced the content of fibronectin in all endothelial cell
cultures [45]. IFNγ treatment selectively elevated the levels
and localization of E-cadherin at cell borders in the cytok-
eratin-positive type 1 cells [45]. This was associated withReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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increased levels of desmosomes and both tight and gap
junctions and a reduction in permeability [57].
In addition to the notable effects on the cytoskeleton,
treatment with IFNγ under low density and growth pro-
moting conditions exerted a profound anti-proliferative,
but mainly cystostatic, effect on cell types 1–4 [38,44].
However, type 5 cells (granulosa-like cells) were not
growth inhibited by IFNγ. In consideration of the anti-
proliferative actions on types 1–4 endothelial cells,
together with the features of cell senescence, it appears
that endothelial cells are generally negatively affected by
IFNγ. This cytokine is produced by local immune cells
[58-61] and may support the cytotoxic effect of TNFα on
luteal endothelial cells [38,111] during corpus luteum
regression.
Class I and II major histocompatibility (MHC) molecules
are expressed in the corpus luteum and are thought to ini-
tiate a transient immune response during corpus luteum
regression [61]. The class I and II MHC molecules are
present on the endothelial and steroidogenic cells in the
bovine corpus luteum. In cytokeratin-positive type 1 and
2 endothelial cells, basal expression of class I major MHC
molecules is low, and increases 7–13 fold following treat-
ment with IFNγ [43]. The class II MHC molecules are not
detectable in un-stimulated cytokeratin-positive endothe-
lial cells, expression of Class II MHC molecules is elevated
in response to IFNγ. Endothelial cell types 3–5 have a high
basal level of expression of Class I MHC antigens, which
is moderately elevated only in type 5 cells. Interferon γ
also induces expression (80 fold increase) of Class II MHC
antigens in type 5 cells [43]. Others have observed that
IFNγ-treated endothelial cells derived from veins express
considerably more Class II molecules than arteries [112].
Given the differences in expression levels for Class II MHC
molecules, this finding could point to a different origin
for types 2 and 5 cells. Additionally, the differential
expression of Class I and Class II molecules translates to
different immunological responses which may help
explain the temporal nature of endothelial cell loss during
corpus luteum regression
Secretion of Chemokines
Regulated on activation, normal T cell expressed and 
secreted (RANTES)
In the corpus luteum, microvascular endothelial cells are
likely to mediate the cyclic accumulation of specific sub-
sets of leukocytes. Eosinophils rapidly accumulate during
the early phase of corpus luteum development, whereas,
the number of macrophages is dramatically increased dur-
ing the late luteal phase [58-61]. The combined action of
adhesion molecules (as described in a previous section)
and chemokines are required to recruit eosinophils and
macrophages into the corpus luteum at precisely defined
stages of the estrous cycle. A chemokine known to stimu-
late eosinophil recruitment, RANTES (regulated on activa-
tion, normal T cell expressed and secreted), is expressed in
the bovine [54,62] and human ovary [63,64]. In vitro stud-
ies indicate that the common cytokeratin-negative bovine
endothelial cells have significantly higher basal RANTES
mRNA levels than do cytokeratin-positive cells [54]. Fur-
thermore, TNFα up-regulates RANTES mRNA in both cell
types. However, in situ hybridization studies indicate that
RANTES mRNA positive macrophages are present in the
former thecal layer of the corpus luteum, not in the corpus
luteum itself, pointing to mRNA levels below the detec-
tion level [62]. Both RANTES mRNA and protein are
present and up regulated by TNFα in cultures of luteinized
granulosa cells from women undergoing in vitro fertiliza-
tion [63]. It is possible that endothelial-like granulosa cell
subpopulations as described by Antczak and Van Blerkom
[51] may be involved in the recruitment of eosinophils.
Additionally, the mRNA for granulocyte-macrophage col-
ony-stimulating factor, a macrophage recruiting factor,
was found in control and TNFα-stimulated cytokeratin-
negative endothelial cells but not cytokeratin-positive
cells [54]. This indicates that the common cytokeratin-
negative endothelial cells may play a role in recruitment
of macrophages during corpus luteum regression [64].
Monocyte chemoattractant protein-1 (MCP-1)
The chemokine, monocyte chemoattractant protein-1
(MCP-1) is produced in the regressing corpus luteum of
rats, pigs, sheep, cows, and women [reviewed by Penny in
[113]]. This chemokine is of particular interest because
once expressed within blood vessels it facilitates the
attachment and migration of immune cells, specifically
monocytes, macrophages, and T-lymphocytes, from the
bloodstream into sites of inflammation. In this regard,
macrophage and lymphocytes have been demonstrated to
accumulate in the regressing corpora lutea of many spe-
cies and have been implicated in phagocytosis of luteal
cells, degradation of extracellular matrix, and secretion of
other pro-inflammatory mediators that may influence
luteal steroidogenesis or apoptosis. Depending on the
species studied, steroidogenic and/or endothelial cells
appear to be the source of MCP-1 [60,113]. The endothe-
lial cells of the bovine corpus luteum are clearly a source
of MCP-1 and respond directly to cytokines, such as TNFα
and IFNγ, with an elevation of MCP-1 mRNA and MCP-1
secretion [114]. However, in contrast to previous in vivo
studies showing that prostaglandin F2α elevates MCP-1
mRNA during induced regression of the corpus luteum
[113], treatment of primary cultures of luteal endothelial
cells with prostaglandin F2α had no effect on MCP-1
mRNA expression or secretion. Further analysis revealed
that these endothelial cells lacked prostaglandin F2α
receptor (FP) mRNA and did not respond to prostaglan-
din F2α with elevations in well-characterized signal trans-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/89
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duction pathways [114]. Since Girsch et al. [115] provided
evidence that some luteal endothelial cells are responsive
to prostaglandin F2α, different laboratory conditions or
endothelial cell types (cytokeratin-positive versus cytoker-
atin-negative cells) may explain the divergent response to
prostaglandin F2α. Thus, whether the stimulatory effect of
prostaglandin F2α on MCP-1 secretion in vivo involves the
activation of endothelial cells directly, or indirectly medi-
ated by cytokine action on steroidogenic cells, endothelial
cells or macrophages remain to be determined. However,
previous studies employing in situ hybridization have not
identified luteal endothelial cells as a source of prostag-
landin F2α receptor mRNA [116].
Granulocyte-macrophage colony-stimulating factor (GM-
CSF)
Granulocyte-macrophage colony-stimulating factor,
another chemokine with macrophage recruiting proper-
ties, has been identified in endothelial cells. The mRNA
for GM-CSF was found in control and TNFα-stimulated
cytokeratin-negative endothelial cells but not cytokeratin-
positive cells [54]. These studies indicate that the com-
mon cytokeratin-negative endothelial cells may play a
role in recruitment of macrophages during corpus luteum
regression. [64].
Relationship to tumor microvascular endothelial 
cells
As mentioned in the introduction, the angiogenesis asso-
ciated with the developing corpus luteum is often com-
pared to tumor-associated angiogenesis
[3,11,12,20,117,118]. The growth and development of
both are critically dependent an adequate supply of blood
vessels. The analogy continues with the dependency on a
number of shared angiogenic factors and vasoactive mol-
ecules, and their receptors. Despite these similarities, the
index of proliferating capillary cells of the newly develop-
ing bovine corpus luteum (40.6 ± 11 %) was consistently
higher than that observed in six different types of malig-
nant tumors in humans (2–5 % for prostate, lung and
mammary carcinomas; and as high as 8–10 % for colon,
carcinomas, renal carcinomas and glioblastomas) [118].
Additional differences were noted in the extent of pericyte
coverage (12–67 %) of the vasculature in these tumors
compared to the developing (60 %) and mature (64 %)
corpus luteum [118]. If coverage of the vasculature with
pericytes is linked to the maturity of the vascular bed, then
these data suggest that both tumor and corpus luteum vas-
culature beds are relatively immature. This functional
immaturity allows the vascular elements to be targeted for
remodeling. Thus, the very active angiogenesis observed
during corpus luteum development is greater than
observed in some tumors. In contrast to tumor angiogen-
esis, the vascular development in the corpus luteum is
tightly regulated by endocrine and paracrine, and auto-
crine factors that regulate ovarian function. The plasticity
of the vasculature of the mature corpus luteum presump-
tively allows for targeted destruction of the capillaries dur-
ing corpus luteum regression. This also requires a tightly
coordinated process in which angiogenic factors are
reduced and angiostatic factors, vasoactive compounds,
cytokines and chemokines are elevated.
Future directions
Much remains to be discovered about the processes that
control vascular development and regression in the cyclic
corpus luteum. Similarly, little is known about the factors
responsible for maintaining the vasculature of the corpus
luteum of pregnancy. Studies with specific microvascular
endothelial cells will enhance efforts to understand which
factors influence this complex physiologic process. New
research is necessary to learn more about the role of the
extracellular matrix and cell-to-cell interactions among
endothelial cells, capillary pericytes, immune cells and
steroidogenic cells. The involvement of steroid receptors
and nitric oxide alone or in combination with vasoactive
peptides and lipids, cytokines and/or chemokines are fer-
tile fields of discovery using in vivo and  in vitro
approaches.
Conclusion
The study of the endothelial cells of the corpus luteum has
provided new insights into the mechanisms required for
normal corpus luteum development, function, and regres-
sion. Much remains to be discovered about the function
of vascular specific growth factors, as well as the pleio-
tropic angiogenic cytokines present during angiogenesis
and angioregression of the corpus luteum. Furthermore,
the specific intracellular signaling pathways that promote
and maintain the vasculature, induce regression of the
vasculature and ultimately the regression of the corpus
luteum remain to be worked out. The field of vascular-bed
heterogeneity is well recognized, yet it remains to be spec-
ified for the vasculature of the corpus luteum of many ani-
mals. The qualitative and quantitative differences in
ovarian angiogenesis in various animal models remains to
be worked out. Research on all of these issues will help sci-
entists to better understand the complexity of a fascinat-
ing biologic process, how blood vessels grow and regress
during the life span of the corpus luteum. Furthermore,
the potential clinical applications of this research are tre-
mendous considering crucial reproductive processes in
which vascular dysfunctions play a role.
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